MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research to evaluate multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major trial objectives were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people, while one of many exploratory goals https://arn2506871322.blogdanica.com/30768438/helping-the-others-realize-the-advantages-of-antidepressant-agent-5